News
IDRSF
3.950
NaN%
--
Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential
TipRanks · 4d ago
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
TipRanks · 12/01 10:15
H.C. Wainwright Sticks to Their Buy Rating for Idorsia Ltd (IDIA)
TipRanks · 11/03 18:05
Kepler Capital Keeps Their Hold Rating on Idorsia Ltd (IDIA)
TipRanks · 11/01 01:48
Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating
TipRanks · 10/27 10:26
Kepler Capital Remains a Hold on Idorsia Ltd (IDIA)
Barchart · 10/12 20:50
Idorsia Ltd (IDIA) Receives a Hold from Kepler Capital
TipRanks · 09/24 01:45
Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts
TipRanks · 09/19 13:35
Weekly Report: what happened at IDRSF last week (0908-0912)?
Weekly Report · 09/15 11:55
Idorsia upgraded to Buy from Neutral at H.C. Wainwright
TipRanks · 09/15 10:15
Weekly Report: what happened at IDRSF last week (0901-0905)?
Weekly Report · 09/08 11:57
Weekly Report: what happened at IDRSF last week (0825-0829)?
Weekly Report · 09/01 11:51
Weekly Report: what happened at IDRSF last week (0818-0822)?
Weekly Report · 08/25 12:05
Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank
TipRanks · 08/22 16:50
Weekly Report: what happened at IDRSF last week (0811-0815)?
Weekly Report · 08/18 11:55
Weekly Report: what happened at IDRSF last week (0804-0808)?
Weekly Report · 08/11 12:04
Weekly Report: what happened at IDRSF last week (0728-0801)?
Weekly Report · 08/04 12:07
Idorsia Ltd Earnings Call: Strong Growth Amid Challenges
TipRanks · 08/01 00:21
Idorsia GAAP EPS of -0.06 CHF, revenue of 72M CHF
Seeking Alpha · 07/30 14:46
More
Webull provides a variety of real-time IDRSF stock news. You can receive the latest news about Idorsia through multiple platforms. This information may help you make smarter investment decisions.
About IDRSF
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.